Nateglinide - Ajinomoto
Alternative Names: A 4166; AY 4166; Fastic; Glinate; Nategurinide; SDZ DJN 608; Senaglinide; Starlix; Starsis; YM 026Latest Information Update: 05 Nov 2023
At a glance
- Originator Ajinomoto
- Developer Ajinomoto; Astellas Pharma; Glenmark Pharmaceuticals Ltd; Novartis
- Class Antihyperglycaemics; Aromatic amino acids; Cyclohexanes; Small molecules
- Mechanism of Action Potassium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Type 2 diabetes mellitus
Most Recent Events
- 11 Jul 2016 Generic equivalent approved in USA for Type-2 diabetes mellitus
- 31 May 2015 Astellas Pharma withdraws NDA for use of nateglinide plus DPP4 inhibitors for Type 2 diabetes mellitus in Japan
- 31 Jul 2014 Astellas Pharma files for approval of nateglinide plus DPP4 inhibitors for Type 2 diabetes mellitus in Japan